Sign In
Buy ABT
Abbott Laboratories Earnings Calls
| Release date | Apr 16, 2026 |
| EPS estimate | $1.14 |
| EPS actual | $1.15 |
| EPS Surprise | 0.88% |
| Revenue estimate | 11B |
| Revenue actual | 11.164B |
| Revenue Surprise | 1.49% |
| Release date | Jan 22, 2026 |
| EPS estimate | $1.50 |
| EPS actual | $1.50 |
| Revenue estimate | 11.8B |
| Revenue actual | 11.459B |
| Revenue Surprise | -2.89% |
| Release date | Oct 15, 2025 |
| EPS estimate | $1.30 |
| EPS actual | $1.30 |
| Revenue estimate | 11.39B |
| Revenue actual | 11.369B |
| Revenue Surprise | -0.182% |
| Release date | Jul 17, 2025 |
| EPS estimate | $1.26 |
| EPS actual | $1.26 |
| Revenue estimate | 11.092B |
| Revenue actual | 11.142B |
| Revenue Surprise | 0.451% |
Last 4 Quarters for Abbott Laboratories
Below you can see how ABT performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Jul 17, 2025 |
| Price on release | $120.51 |
| EPS estimate | $1.26 |
| EPS actual | $1.26 |
| Date | Price |
|---|---|
| Jul 11, 2025 | $132.02 |
| Jul 14, 2025 | $132.03 |
| Jul 15, 2025 | $131.49 |
| Jul 16, 2025 | $131.74 |
| Jul 17, 2025 | $120.51 |
| Jul 18, 2025 | $123.67 |
| Jul 21, 2025 | $124.42 |
| Jul 22, 2025 | $125.73 |
| Jul 23, 2025 | $125.83 |
| 4 days before | -8.72% |
| 4 days after | 4.41% |
| On release day | 2.62% |
| Change in period | -4.69% |
| Release date | Oct 15, 2025 |
| Price on release | $129.45 |
| EPS estimate | $1.30 |
| EPS actual | $1.30 |
| Date | Price |
|---|---|
| Oct 09, 2025 | $133.31 |
| Oct 10, 2025 | $132.57 |
| Oct 13, 2025 | $131.38 |
| Oct 14, 2025 | $133.27 |
| Oct 15, 2025 | $129.45 |
| Oct 16, 2025 | $127.63 |
| Oct 17, 2025 | $128.54 |
| Oct 20, 2025 | $129.51 |
| Oct 21, 2025 | $127.54 |
| 4 days before | -2.90% |
| 4 days after | -1.48% |
| On release day | -1.41% |
| Change in period | -4.33% |
| Release date | Jan 22, 2026 |
| Price on release | $108.60 |
| EPS estimate | $1.50 |
| EPS actual | $1.50 |
| Date | Price |
|---|---|
| Jan 15, 2026 | $123.52 |
| Jan 16, 2026 | $121.76 |
| Jan 20, 2026 | $121.12 |
| Jan 21, 2026 | $120.73 |
| Jan 22, 2026 | $108.60 |
| Jan 23, 2026 | $107.42 |
| Jan 26, 2026 | $108.77 |
| Jan 27, 2026 | $108.23 |
| Jan 28, 2026 | $106.05 |
| 4 days before | -12.08% |
| 4 days after | -2.35% |
| On release day | -1.09% |
| Change in period | -14.14% |
| Release date | Apr 16, 2026 |
| Price on release | $95.46 |
| EPS estimate | $1.14 |
| EPS actual | $1.15 |
| EPS surprise | 0.88% |
| Date | Price |
|---|---|
| Apr 10, 2026 | $100.30 |
| Apr 13, 2026 | $100.65 |
| Apr 14, 2026 | $101.07 |
| Apr 15, 2026 | $101.50 |
| Apr 16, 2026 | $95.46 |
| Apr 17, 2026 | $96.83 |
| Apr 20, 2026 | $96.02 |
| Apr 21, 2026 | $92.75 |
| Apr 22, 2026 | $91.74 |
| 4 days before | -4.83% |
| 4 days after | -3.90% |
| On release day | 1.44% |
| Change in period | -8.53% |
Abbott Laboratories Earnings Call Transcript Summary of Q1 2026
Abbott reported Q1 2026 results largely in line with expectations: adjusted EPS of $1.15 and comparable sales up 3.7%. The company completed the acquisition of Exact Sciences (closed March 23), which management expects to add roughly $3 billion of incremental sales in 2026 and to accelerate Abbott's long-term sales growth. Business highlights: Diagnostics +2% (Core Lab +3%, Cancer Diagnostics +13%, Rapid/Molecular down due to a weak respiratory season), Medical Devices +8.5% (strong Electrophysiology, Rhythm Management, Heart Failure), Nutrition showing early signs of volume recovery following 2025 pricing actions, EPD +9% with broad international strength, and CGM sales of $2 billion (CGM growth expected to re-accelerate to double digits in Q2). Foreign exchange provided a favorable impact in Q1 and is expected to be ~+1% for the full year. Abbott issued full-year 2026 sales growth guidance of 6.5%–7.5% on a comparable basis (now including Exact Sciences in both years) and updated full-year adjusted EPS midpoint to $5.48 (down $0.20 vs. prior midpoint) reflecting expected dilution from the Exact Sciences acquisition. Management reiterated confidence in an acceleration of growth in the second half of 2026 driven by Nutrition execution, Core Lab and Electrophysiology product launches/market recovery, continued strength in EPD and devices, and the integration of Exact Sciences. Key near-term risks called out include a weaker-than-expected respiratory season, timing of respiratory demand recovery, ongoing China VBP effects in diagnostics (improving but still modeled as a headwind), and macro/geo-political supply-chain dynamics.
